JP2017532365A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2017532365A5 JP2017532365A5 JP2017525311A JP2017525311A JP2017532365A5 JP 2017532365 A5 JP2017532365 A5 JP 2017532365A5 JP 2017525311 A JP2017525311 A JP 2017525311A JP 2017525311 A JP2017525311 A JP 2017525311A JP 2017532365 A5 JP2017532365 A5 JP 2017532365A5
- Authority
- JP
- Japan
- Prior art keywords
- collagen
- pharmaceutical composition
- chain polypeptide
- protein
- amino acid
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 102000008186 Collagen Human genes 0.000 claims 26
- 108010035532 Collagen Proteins 0.000 claims 26
- 229920001436 collagen Polymers 0.000 claims 26
- 239000008194 pharmaceutical composition Substances 0.000 claims 18
- 229920001184 polypeptide Polymers 0.000 claims 18
- 102000004196 processed proteins & peptides Human genes 0.000 claims 18
- 108090000765 processed proteins & peptides Proteins 0.000 claims 18
- 102000004169 proteins and genes Human genes 0.000 claims 14
- 108090000623 proteins and genes Proteins 0.000 claims 14
- 150000001413 amino acids Chemical group 0.000 claims 12
- 102000002067 Protein Subunits Human genes 0.000 claims 9
- 108010001267 Protein Subunits Proteins 0.000 claims 9
- 208000003215 hereditary nephritis Diseases 0.000 claims 7
- 208000024985 Alport syndrome Diseases 0.000 claims 4
- 210000004027 cell Anatomy 0.000 claims 4
- PMMYEEVYMWASQN-UHFFFAOYSA-N dl-hydroxyproline Natural products OC1C[NH2+]C(C([O-])=O)C1 PMMYEEVYMWASQN-UHFFFAOYSA-N 0.000 claims 4
- PMMYEEVYMWASQN-DMTCNVIQSA-N Hydroxyproline Chemical compound O[C@H]1CN[C@H](C(O)=O)C1 PMMYEEVYMWASQN-DMTCNVIQSA-N 0.000 claims 3
- 238000003556 assay Methods 0.000 claims 3
- 239000000539 dimer Substances 0.000 claims 3
- 208000006750 hematuria Diseases 0.000 claims 3
- 238000004519 manufacturing process Methods 0.000 claims 3
- 201000001474 proteinuria Diseases 0.000 claims 3
- BJBUEDPLEOHJGE-IMJSIDKUSA-N trans-3-hydroxy-L-proline Chemical compound O[C@H]1CC[NH2+][C@@H]1C([O-])=O BJBUEDPLEOHJGE-IMJSIDKUSA-N 0.000 claims 3
- BJBUEDPLEOHJGE-UHFFFAOYSA-N (2R,3S)-3-Hydroxy-2-pyrolidinecarboxylic acid Natural products OC1CCNC1C(O)=O BJBUEDPLEOHJGE-UHFFFAOYSA-N 0.000 claims 2
- FWMNVWWHGCHHJJ-SKKKGAJSSA-N 4-amino-1-[(2r)-6-amino-2-[[(2r)-2-[[(2r)-2-[[(2r)-2-amino-3-phenylpropanoyl]amino]-3-phenylpropanoyl]amino]-4-methylpentanoyl]amino]hexanoyl]piperidine-4-carboxylic acid Chemical compound C([C@H](C(=O)N[C@H](CC(C)C)C(=O)N[C@H](CCCCN)C(=O)N1CCC(N)(CC1)C(O)=O)NC(=O)[C@H](N)CC=1C=CC=CC=1)C1=CC=CC=C1 FWMNVWWHGCHHJJ-SKKKGAJSSA-N 0.000 claims 2
- 208000025760 Benign familial haematuria Diseases 0.000 claims 2
- 206010008111 Cerebral haemorrhage Diseases 0.000 claims 2
- 208000032843 Hemorrhage Diseases 0.000 claims 2
- 230000005856 abnormality Effects 0.000 claims 2
- 230000000740 bleeding effect Effects 0.000 claims 2
- 208000020832 chronic kidney disease Diseases 0.000 claims 2
- 230000007812 deficiency Effects 0.000 claims 2
- 239000003814 drug Substances 0.000 claims 2
- 201000000523 end stage renal failure Diseases 0.000 claims 2
- 210000000585 glomerular basement membrane Anatomy 0.000 claims 2
- 229960002591 hydroxyproline Drugs 0.000 claims 2
- 201000006370 kidney failure Diseases 0.000 claims 2
- 239000000203 mixture Substances 0.000 claims 2
- 239000000546 pharmaceutical excipient Substances 0.000 claims 2
- 108010050451 2-oxoglutarate 3-dioxygenase proline Proteins 0.000 claims 1
- 206010002329 Aneurysm Diseases 0.000 claims 1
- 201000002431 Autosomal dominant Alport syndrome Diseases 0.000 claims 1
- 208000014644 Brain disease Diseases 0.000 claims 1
- 208000029812 Cerebral Small Vessel disease Diseases 0.000 claims 1
- 208000032274 Encephalopathy Diseases 0.000 claims 1
- 208000002111 Eye Abnormalities Diseases 0.000 claims 1
- 208000028782 Hereditary disease Diseases 0.000 claims 1
- KDXKERNSBIXSRK-UHFFFAOYSA-N Lysine Natural products NCCCCC(N)C(O)=O KDXKERNSBIXSRK-UHFFFAOYSA-N 0.000 claims 1
- 239000004472 Lysine Substances 0.000 claims 1
- 241000124008 Mammalia Species 0.000 claims 1
- 108010074633 Mixed Function Oxygenases Proteins 0.000 claims 1
- 102000008109 Mixed Function Oxygenases Human genes 0.000 claims 1
- 102000018399 Prolyl 3-hydroxylases Human genes 0.000 claims 1
- 108010043005 Prolyl Hydroxylases Proteins 0.000 claims 1
- 102000004079 Prolyl Hydroxylases Human genes 0.000 claims 1
- 102000004669 Protein-Lysine 6-Oxidase Human genes 0.000 claims 1
- 108010003894 Protein-Lysine 6-Oxidase Proteins 0.000 claims 1
- 208000001647 Renal Insufficiency Diseases 0.000 claims 1
- 201000002429 X-linked Alport syndrome Diseases 0.000 claims 1
- 239000003963 antioxidant agent Substances 0.000 claims 1
- 201000002430 autosomal recessive Alport syndrome Diseases 0.000 claims 1
- 210000002469 basement membrane Anatomy 0.000 claims 1
- 239000000090 biomarker Substances 0.000 claims 1
- 230000021164 cell adhesion Effects 0.000 claims 1
- 230000024245 cell differentiation Effects 0.000 claims 1
- 230000012292 cell migration Effects 0.000 claims 1
- 230000002490 cerebral effect Effects 0.000 claims 1
- 239000002738 chelating agent Substances 0.000 claims 1
- 230000002950 deficient Effects 0.000 claims 1
- 201000010099 disease Diseases 0.000 claims 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 1
- 230000004064 dysfunction Effects 0.000 claims 1
- 208000028208 end stage renal disease Diseases 0.000 claims 1
- YSMODUONRAFBET-UHNVWZDZSA-N erythro-5-hydroxy-L-lysine Chemical group NC[C@H](O)CC[C@H](N)C(O)=O YSMODUONRAFBET-UHNVWZDZSA-N 0.000 claims 1
- 230000001434 glomerular Effects 0.000 claims 1
- 208000020658 intracerebral hemorrhage Diseases 0.000 claims 1
- 238000007917 intracranial administration Methods 0.000 claims 1
- 238000007918 intramuscular administration Methods 0.000 claims 1
- 238000007912 intraperitoneal administration Methods 0.000 claims 1
- 238000007913 intrathecal administration Methods 0.000 claims 1
- 238000001990 intravenous administration Methods 0.000 claims 1
- 238000010253 intravenous injection Methods 0.000 claims 1
- 238000007914 intraventricular administration Methods 0.000 claims 1
- 239000007951 isotonicity adjuster Substances 0.000 claims 1
- 230000007774 longterm Effects 0.000 claims 1
- 238000005259 measurement Methods 0.000 claims 1
- 210000003205 muscle Anatomy 0.000 claims 1
- 230000009984 peri-natal effect Effects 0.000 claims 1
- 125000001500 prolyl group Chemical group [H]N1C([H])(C(=O)[*])C([H])([H])C([H])([H])C1([H])[H] 0.000 claims 1
- 210000004129 prosencephalon Anatomy 0.000 claims 1
- 238000001525 receptor binding assay Methods 0.000 claims 1
- 238000007920 subcutaneous administration Methods 0.000 claims 1
- 208000019553 vascular disease Diseases 0.000 claims 1
Applications Claiming Priority (7)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201462029135P | 2014-07-25 | 2014-07-25 | |
| US62/029,135 | 2014-07-25 | ||
| US201462072490P | 2014-10-30 | 2014-10-30 | |
| US62/072,490 | 2014-10-30 | ||
| US201562128729P | 2015-03-05 | 2015-03-05 | |
| US62/128,729 | 2015-03-05 | ||
| PCT/US2015/041712 WO2016014781A1 (en) | 2014-07-25 | 2015-07-23 | Collagen iv replacement |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2017532365A JP2017532365A (ja) | 2017-11-02 |
| JP2017532365A5 true JP2017532365A5 (https=) | 2018-09-06 |
Family
ID=55163752
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2017525311A Pending JP2017532365A (ja) | 2014-07-25 | 2015-07-23 | コラーゲンｉｖの置き換え |
Country Status (6)
| Country | Link |
|---|---|
| US (1) | US20180207240A1 (https=) |
| EP (1) | EP3171889A4 (https=) |
| JP (1) | JP2017532365A (https=) |
| AU (1) | AU2015292582A1 (https=) |
| CA (1) | CA2955481A1 (https=) |
| WO (1) | WO2016014781A1 (https=) |
Families Citing this family (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US11376278B2 (en) | 2016-08-11 | 2022-07-05 | Sulfilatec, Inc. | Compositions and methods for treating disease |
| GB201717301D0 (en) * | 2017-10-20 | 2017-12-06 | Nordic Bioscience As | Type xvi collagen assay |
| US20210275558A1 (en) * | 2018-07-25 | 2021-09-09 | Boehringer Ingelheim International Gmbh | Methods for treating, pharmaceutical compositions and uses thereof |
| JPWO2021049633A1 (https=) * | 2019-09-11 | 2021-03-18 | ||
| US12164185B2 (en) * | 2020-02-14 | 2024-12-10 | Tdk Corporation | Optical modulation element |
| GB202003618D0 (en) | 2020-03-12 | 2020-04-29 | Univ Bristol | Gene Therapy |
| EP4255427B1 (en) * | 2020-12-03 | 2024-11-06 | Delta 4 GmbH | Clopidogrel for use in the treatment of focal segmental glomerulosclerosis (fsgs) |
| CN114149502A (zh) * | 2021-12-23 | 2022-03-08 | 杭州百凌生物科技有限公司 | 一种四型胶原蛋白ɑ3的抗体、检测试剂盒及其应用 |
| CN115960211B (zh) * | 2022-12-23 | 2023-11-21 | 江苏创健医疗科技股份有限公司 | 一种重组人源ⅵ型胶原蛋白及其制备方法和应用 |
| WO2025193938A1 (en) * | 2024-03-13 | 2025-09-18 | Oregon Health & Science University | Delivery of type iv collagen alpha chain using a split intein dual aav vector |
| CN119286901B (zh) * | 2024-11-21 | 2025-09-09 | 西安巨子生物基因技术股份有限公司 | 一种重组iv型胶原蛋白及其制备方法和应用 |
| CN120731923B (zh) * | 2025-09-05 | 2025-11-04 | 内蒙古医科大学附属医院(内蒙古自治区心血管研究所) | 一种Alport综合征小鼠NMD逃逸模型的构建方法及其应用 |
Family Cites Families (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6440729B1 (en) * | 1995-06-30 | 2002-08-27 | University Of Kansas Medical Center | Treating angiogenesis-mediated diseases with the α2 monomer of type IV collagen |
| AU748751B2 (en) * | 1998-03-27 | 2002-06-13 | University Of Kansas Medical Center | The use of isolated domains of type IV collagen to modify cell and tissue interactions |
| US6812339B1 (en) * | 2000-09-08 | 2004-11-02 | Applera Corporation | Polymorphisms in known genes associated with human disease, methods of detection and uses thereof |
| AU2002329643B2 (en) * | 2001-07-27 | 2006-11-16 | University Of Kansas Medical Center | Crystallized structure of type IV collagen NC1 domain hexamer |
| US7183383B2 (en) * | 2002-03-20 | 2007-02-27 | The University Of Arkansas For Medical Sciences | Uses of collagen IV |
| US7608413B1 (en) * | 2005-03-25 | 2009-10-27 | Celera Corporation | Kidney disease targets and uses thereof |
| WO2011123811A2 (en) * | 2010-04-02 | 2011-10-06 | The Board Of Trustees Of The Leland Stanford Junior University | Production of post-translationally hydroxylated recombinant proteins in bacteria |
| UA116639C2 (uk) * | 2012-10-09 | 2018-04-25 | Рег'Юлес Терап'Ютікс Інк. | Способи лікування синдрому альпорта |
| US20180055913A1 (en) * | 2014-07-29 | 2018-03-01 | Vanderbilt University | Recombinant collagen iv surrogates and uses thereof |
-
2015
- 2015-07-23 CA CA2955481A patent/CA2955481A1/en not_active Abandoned
- 2015-07-23 AU AU2015292582A patent/AU2015292582A1/en not_active Abandoned
- 2015-07-23 US US15/328,215 patent/US20180207240A1/en not_active Abandoned
- 2015-07-23 WO PCT/US2015/041712 patent/WO2016014781A1/en not_active Ceased
- 2015-07-23 JP JP2017525311A patent/JP2017532365A/ja active Pending
- 2015-07-23 EP EP15824092.9A patent/EP3171889A4/en not_active Withdrawn
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2017532365A5 (https=) | ||
| Campbell | Long-term neprilysin inhibition—implications for ARNIs | |
| Jensen et al. | Activation of GLP-1 receptors on vascular smooth muscle cells reduces the autoregulatory response in afferent arterioles and increases renal blood flow | |
| Basile et al. | Pathophysiology of acute kidney injury | |
| KR101671406B1 (ko) | 신장 장애 치료용 조성물 및 방법 | |
| JP6238934B2 (ja) | 内在化ペプチド連結薬剤と抗炎症剤との共投与 | |
| CN115192719B (zh) | 用于治疗肺血管疾病的组合物和方法 | |
| CN111542335A (zh) | 炎症性肠病的治疗药 | |
| TW202142254A (zh) | 用於治療或預防纖維化、肥大或心臟衰竭之骨髓源性生長因子 | |
| Wiśniewski | Design of oxytocin analogs | |
| JP2018515101A5 (https=) | ||
| CA2971414A1 (en) | Methods of treating tissue calcification | |
| JP7471824B2 (ja) | 高血糖症の治療及び予防のためのペプチド | |
| CA2955481A1 (en) | Collagen iv replacement | |
| WO2018018010A1 (en) | Fgf mutants and uses thereof | |
| JP2020147583A (ja) | リポジストロフィーおよびインスリン産生の欠損またはインスリンシグナル伝達の欠損と関連する代謝性障害を処置する方法 | |
| JP2024502463A (ja) | 治療指数を改善するためのプラスミン耐性ペプチド | |
| Bankir et al. | Vaptans or voluntary increased hydration to protect the kidney: how do they compare? | |
| US9060977B2 (en) | Heparin binding epidermal growth factor (HB-EGF) for use in methods of treating and preventing intestinal injury related to hemorrhagic shock and resuscitation | |
| US10517926B2 (en) | Oligopeptide having proinflammatory cytokine secretion-inhibiting activity | |
| JP2009510134A (ja) | Ｄｐｐ−ｉｖ阻害剤およびガストリン化合物の組み合わせ使用 | |
| CN109475604B (zh) | 长效型clr/ramp激动剂的配量和用途 | |
| US20200031873A1 (en) | Repurposing cell penetrating peptides and their novel derivatives and iopromide and iodo-aryl carbonates for treatment of senescence-related diseases and disorders | |
| US12122853B2 (en) | Compositions and methods of inhibiting the binding of plasma IGG autoantibodies to serotonin 2A receptor | |
| US9474789B2 (en) | Methods and compositions for promoting organ growth and development |